📊 NRXS Key Takeaways
Is NRXS a Good Investment? Thesis Analysis
Neuraxis exhibits severe fundamental distress with substantial operating losses despite high gross margins, indicating critical execution and operational efficiency issues. The company is burning cash rapidly with negative free cash flow of -6.5M against only 3.6M in annual revenue, while relying on depleting cash reserves to sustain operations.
Why Buy NRXS? Key Strengths
- Strong gross margin of 84.2% indicates viable product economics
- Solid liquidity position with 2.05x current ratio and 5.0M cash reserves
- Low leverage with 0.05x debt-to-equity ratio provides financial flexibility
NRXS Investment Risks to Consider
- Massive operating losses of -7.8M with -219.4% operating margin indicate unsustainable business model
- Negative free cash flow of -6.5M annually will deplete 5.0M cash reserves within approximately 9 months at current burn rate
- Revenue stagnation (0.0% YoY growth) combined with rising operating expenses demonstrates inability to scale profitably
- Highly negative returns on equity (-229.5%) and assets (-121.8%) show value destruction
- Operating cash flow of -6.4M indicates core business operations are not self-sustaining
Key Metrics to Watch
- Operating cash flow trajectory and path to cash flow breakeven
- Revenue growth acceleration and operating expense control
- Cash runway and timeline to profitability or need for capital raise
- Gross margin sustainability as company scales
- Customer acquisition and retention metrics
NRXS Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 2.05x current ratio provides a solid financial cushion.
NRXS Profitability Ratios
NRXS vs Healthcare Sector
How Neuraxis, INC compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is NRXS Overvalued or Undervalued?
Based on fundamental analysis, Neuraxis, INC has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
NRXS Balance Sheet & Liquidity
NRXS 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: Neuraxis, INC's revenue has grown significantly by 33% over the 5-year period, indicating strong business expansion. The most recent EPS of $-1.22 indicates the company is currently unprofitable.
NRXS Growth Metrics (YoY)
NRXS Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $666.6K | -$1.7M | $-0.24 |
| Q2 2025 | $611.5K | -$1.7M | $-0.22 |
| Q1 2025 | $646.6K | -$2.1M | $-0.32 |
| Q3 2024 | $477.5K | -$1.8M | $-0.25 |
| Q2 2024 | $611.5K | -$2.1M | $-0.42 |
| Q1 2024 | $646.6K | -$2.1M | $-0.32 |
| Q3 2023 | $477.5K | -$1.2M | $-1.14 |
| Q2 2023 | $646.0K | -$1.2M | $-0.87 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
NRXS Capital Allocation
NRXS SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for Neuraxis, INC (CIK: 0001933567)
📋 Recent SEC Filings
❓ Frequently Asked Questions about NRXS
What is the AI rating for NRXS?
Neuraxis, INC (NRXS) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are NRXS's key strengths?
Claude: Strong gross margin of 84.2% indicates viable product economics. Solid liquidity position with 2.05x current ratio and 5.0M cash reserves.
What are the risks of investing in NRXS?
Claude: Massive operating losses of -7.8M with -219.4% operating margin indicate unsustainable business model. Negative free cash flow of -6.5M annually will deplete 5.0M cash reserves within approximately 9 months at current burn rate.
What is NRXS's revenue and growth?
Neuraxis, INC reported revenue of $3.6M.
Does NRXS pay dividends?
Neuraxis, INC does not currently pay dividends.
Where can I find NRXS SEC filings?
Official SEC filings for Neuraxis, INC (CIK: 0001933567) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is NRXS's EPS?
Neuraxis, INC has a diluted EPS of $-0.95.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is NRXS a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Neuraxis, INC has a STRONG SELL rating with 92% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is NRXS stock overvalued or undervalued?
Valuation metrics for NRXS: ROE of -229.5% (sector avg: 15%), net margin of -218.5% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy NRXS stock in 2026?
Our dual AI analysis gives Neuraxis, INC a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is NRXS's free cash flow?
Neuraxis, INC's operating cash flow is $-6.4M, with capital expenditures of $31.2K. FCF margin is -181.1%.
How does NRXS compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -218.5% (avg: 12%), ROE -229.5% (avg: 15%), current ratio 2.05 (avg: 2).